Company profile TSHA
There is not enough data for Taysha Gene Therapies - Rett syndrome treatment to provide analysis
There is not enough data for Taysha Gene Therapies - Rett syndrome treatment to provide correlation calculation
There is not enough data for Taysha Gene Therapies - Rett syndrome treatment to provide analysis
After 39 days of this quarter the interest is at 348.0. Based on that we can calculate that during remaining 52 days it will total up to 812.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 539 | 711 31.9% QoQ | 475 -33.2% QoQ | 679 42.9% QoQ |
| 2020 | 768 42.5% YoY 13.1% QoQ | 588 -17.3% YoY -23.4% QoQ | 477 0.4% YoY -18.9% QoQ | 564 -16.9% YoY 18.2% QoQ |
| 2021 | 851 10.8% YoY 50.9% QoQ | 780 32.7% YoY -8.3% QoQ | 675 41.5% YoY -13.5% QoQ | 681 20.7% YoY 0.9% QoQ |
| 2022 | 827 -2.8% YoY 21.4% QoQ | 781 0.1% YoY -5.6% QoQ | 551 -18.4% YoY -29.4% QoQ | 720 5.7% YoY 30.7% QoQ |
| 2023 | 897 8.5% YoY 24.6% QoQ | 777 -0.5% YoY -13.4% QoQ | 554 0.5% YoY -28.7% QoQ | 825 14.6% YoY 48.9% QoQ |
| 2024 | 348 -61.2% YoY -57.8% QoQ | - | - | - |
The average 5 years interest of gene therapy was 53.9 per week. The last year interest of gene therapy compared to the last 5 years has changed by 7.37%. The interest for gene therapy is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 10.84%.
After 34 days of this quarter the interest is at 93.0. Based on that we can calculate that during remaining 58 days it will total up to 252.0. central nervous system diseases expected interest is significantly lower compared to same quarter last year (-49.4%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 0 |
| 2019 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 |
| 2022 | 42 inf% YoY inf% QoQ | 460 inf% YoY 995.2% QoQ | 296 inf% YoY -35.7% QoQ | 498 inf% YoY 68.2% QoQ |
| 2023 | 477 1035.7% YoY -4.2% QoQ | 403 -12.4% YoY -15.5% QoQ | 303 2.4% YoY -24.8% QoQ | 93 -81.3% YoY -69.3% QoQ |
The average 5 years interest of central nervous system diseases was 9.89 per week. The last year interest of central nervous system diseases compared to the last 5 years has changed by 210.11%. This is something to be checked. This didn't exist 5 years ago.
After 39 days of this quarter the interest is at 35.0. Based on that we can calculate that during remaining 52 days it will total up to 82.0. Taysha Gene Therapies stock expected interest is significantly lower compared to previous quarter (-54.4%) and same quarter last year (-57.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 91 inf% QoQ | 0 -100.0% QoQ | 52 inf% QoQ |
| 2020 | 73 inf% YoY 40.4% QoQ | 150 64.8% YoY 105.5% QoQ | 44 inf% YoY -70.7% QoQ | 98 88.5% YoY 122.7% QoQ |
| 2021 | 333 356.2% YoY 239.8% QoQ | 63 -58.0% YoY -81.1% QoQ | 52 18.2% YoY -17.5% QoQ | 53 -45.9% YoY 1.9% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 115 82.5% YoY inf% QoQ | 58 11.5% YoY -49.6% QoQ | 98 84.9% YoY 69.0% QoQ |
| 2023 | 192 inf% YoY 95.9% QoQ | 54 -53.0% YoY -71.9% QoQ | 198 241.4% YoY 266.7% QoQ | 180 83.7% YoY -9.1% QoQ |
| 2024 | 35 -81.8% YoY -80.6% QoQ | - | - | - |
The average 5 years interest of Taysha Gene Therapies stock was 7.43 per week. The last year interest of Taysha Gene Therapies stock compared to the last 5 years has changed by 63.26%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 258.88%.
There is not enough data for TSHA news to provide analysis
There is not enough data for TSHA news to provide correlation calculation
There is not enough data for TSHA news to provide analysis
There is not enough data for TSHA clinical trials to provide analysis
There is not enough data for TSHA clinical trials to provide correlation calculation
There is not enough data for TSHA clinical trials to provide analysis
There is not enough data for TSHA pipeline to provide analysis
There is not enough data for TSHA pipeline to provide correlation calculation
There is not enough data for TSHA pipeline to provide analysis
There is not enough data for adeno-associated virus gene therapy to provide analysis
There is not enough data for adeno-associated virus gene therapy to provide correlation calculation
There is not enough data for adeno-associated virus gene therapy to provide analysis
There is not enough data for monogenic diseases treatment to provide analysis
There is not enough data for monogenic diseases treatment to provide correlation calculation
There is not enough data for monogenic diseases treatment to provide analysis